Topic: Treanda
Just as Teva Pharmaceuticals (TEVA) hopes to wrap up its $6.2 billion acquisition of Cephalon (CEPH), the biotech company has been asked by the...
On Monday Teva (TEVA) announced its intention to buy Cephalon, Inc. (CEPH) for $6.8 billion in cash. If successful, this deal will expand Teva's...
Treanda may be used to treat non-Hodgkin lymphoma, and also b-cell leukemia. Treanda is a drug that is often used after other drugs have not done their jobs in putting a stop to the progression of these cancer types. Anyone that has ...
Cephalon (CEPH) Q2 2010 Earnings Call July 27, 2010 5:00 pm ET. In the United States, after only two years on the market, TREANDA has helped over 20,000 patients. As many of you know, the Study Group of Indolent Lymphomas ...
Cephalon (CEPH) Q1 2010 Earnings Call May 04, 2010 5:00 pm ET. Even after paying for Ception Therapeutics and Mepha AG, both of which closed shortly after the quarter ended, we have approximately $1 billion in cash on hand. Ception Therapeutics ...
CEPH) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA? (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with ...
Cephalon, Inc. (CEPH) Q3 2009 Earnings Call October 27, 2009 5:00 pm ET. Net sales for the third quarter of 2009 grew 9% to $535 million and adjusted net income grew 36% to $126.7 million exceeding the high end of ...
CEPH) today announced that the Journal of Clinical Oncology has published data from a pivotal phase 3 study demonstrating that TREANDA (bendamustine HCl) for Injection improved clinical outcomes when compared to chlorambucil in patients with chronic lymphocytic leukemia (CLL). Though the exact ...
Cephalon, Inc. (CEPH) Q2 2009 Earnings Call August 04, 2009 5:00 pm ET. 0Speaking on today's call will be Dr. Frank Baldino, Chief Executive Officer, Bob Roche, Worldwide Pharmaceutical Operations, and Kevin Buchi, Chief Financial Officer. We filed an sNDA ...
Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy than Chlorambucil in CLL Blood marrow normalised in 31% (versus 2%) of patients, with manageable side-effects. Professor Wolfgang U. Knauf of the Onkologische Gemeinschaftspraxis, Frankfurter Diakonie Kliniken, Frankfurt, Germany, who led the study ...
